A Phase 1 Study of Androgen Receptor (AR) Antagonist JNJ-56021927 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Phase 1 Study of Androgen Receptor (AR) Antagonist JNJ-56021927 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Apalutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Janssen Pharmaceutical KK
  • Most Recent Events

    • 07 Dec 2017 Planned End Date changed from 14 Mar 2019 to 15 May 2020.
    • 07 Dec 2017 Planned primary completion date changed from 17 Sep 2018 to 15 May 2020.
    • 23 Jun 2017 Planned End Date changed from 17 Sep 2018 to 14 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top